Articles from Corza Medical Inc.

TAUNTON, U.K., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Corza Medical, a leading global manufacturer of surgical technologies and medical device components announced today the launch of its Biomedical Textiles Innovation Lab, a state-of-the-art facility designed to help OEM partners rapidly prototype, test, and optimize textile-based medical materials.

PARSIPPANY, New Jersey, July 07, 2025 (GLOBE NEWSWIRE) -- Corza Medical, a leading global medical technology company, today announced the launch of its expanded Onatec Ophthalmic Suture Portfolio. This marks a significant extension of the product range, making it easier for surgeons worldwide to find the right Onatec suture solution for their ophthalmic procedures.

WESTWOOD, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Corza Medical announced that Carla da Luz Boren, J.D., the Company’s chief human resources officer, has been named among the Top 50 Women Leaders in Healthcare Technology for 2024 by The Healthcare Technology Report (THTR). Ranked fifth on this prestigious list, Boren received recognition for her exceptional leadership, strategic vision, and invaluable contributions to Corza Medical’s growth and success.

Product Launch Introduces Onatec Ophthalmic Microsurgical Sutures at American Academy of Ophthalmology Conference

WESTWOOD, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Corza Medical (“Corza” or the “Company”), a leading global medical technology company committed to remarkable service, trusted performance and outstanding value, has been awarded the respected Global Excellence Award for "Most Innovative Wound Closure Products Manufacturer - 2024 USA" by Global Health & Pharma Magazine (GPH). This recognition highlights the company’s commitment to excellence in providing high-performance technologies and solutions that enhance surgical outcomes.

WESTWOOD, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Corza Medical (“Corza” or the “Company”) is pleased to announce the appointment of Jason Abair as its new Vice President, Legal & Chief Compliance Officer. With over 20 years of legal experience in the medical device and pharmaceutical sectors, Jason brings a wealth of expertise to Corza Medical.

WESTWOOD, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Corza Medical (“Corza” or the “Company”) is proud to announce the appointment of Derek Chaves as its new Chief Financial Officer (CFO), effective July 8, 2024. Corza Medical, a rapidly growing global leader in medical technology and innovative surgical solutions, is recognized for its comprehensive approach to excellence in customer service and partnerships. Derek’s appointment underscores Corza’s commitment to scaling operations and driving further growth in a complex and dynamic market landscape.

Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies

WESTWOOD, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Corza Medical successfully closed its previously announced acquisition of the TachoSil manufacturing operations in Linz, Austria, part of Takeda’s global production network. TachoSil is a best-in-class surgical patch trusted by medical professionals across the globe.    Corza Medical acquired the commercial rights for TachoSil in January 2021. The acquisition of the manufacturing operations will enable Corza Medical to further deliver exceptional value to its customers by combining operational excellence with its commercial excellence engine. It will also allow the company to control manufacturing priorities directly, accelerating enhanced service levels and support to customers globally.     “The acquisition of TachoSil manufacturing operations marks a significant milestone for Corza Medical. We are excited to have completed the acquisition successfully and welcome the employees transferring from Takeda," said Tom Testa, CEO of Corza Medical. "This acquisition will enable us to enhance our product offerings and better serve our customers. We are committed to investing in TachoSil to improve patient care and deliver innovative solutions to surgeons worldwide.”     Executive Chairman Gregory T. Lucier of Corza Medical added, "The investment to own the TachoSil manufacturing operations in Linz will help streamline the supply chain and build a stronger operational capability for our Biosurgery business. We are confident that with the Linz facilities as part of our operations, we will enhance the support for our customers and further deliver on Corza's brand promise of remarkable service, trusted performance, and outstanding value to meet the needs of healthcare professionals."     "By taking ownership of the entire manufacturing process, we will be able to accelerate our growth by increasing our manufacturing capacity and serving new countries. We are excited to advance patient care everywhere in the world,” said Thierry Leclercq Corza Medical’s SVP, GM Biosurgery.     Corza Medical is a portfolio company of GTCR, a leading private equity firm, which helped create and build the business in partnership with Gregory T. Lucier. With a focused commitment to remarkable service, trusted performance, and outstanding economic value to customers, Corza Medical has the experience and resources to continue investing in TachoSil for the benefit of its surgeons, partners, and patients around the world.      About Corza Medical   Corza Medical is a leading global manufacturer of innovative surgical technologies. With a global team of over 3,000 employees supporting clinicians, distributor-partners, and medical device companies worldwide, Corza provides healthcare professionals a platform of surgical technologies with many industry-leading brands, including Quill® barbed sutures, Sharpoint® Plus and Look™ surgical sutures, Katena® reusable and Blink™ single-use ophthalmic instruments, Barron corneal transplant devices, Sharpoint® microsurgical knives, and the TachoSil® fibrin sealant patch. For more information, please visit www.corza.com.      About GTCR Founded in 1980, GTCR is a leading private equity firm that pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors. Since its inception, GTCR has invested more than $25 billion in over 270 companies, and the firm currently manages more than $40 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com. Follow us on LinkedIn.

FENTON, Mo., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Corza Medical has announced the opening of its new Ophthalmology Center of Technology and Innovation. The state-of-the-art facility is aimed at advancing the development of next-generation devices for ophthalmic surgeries and other eye treatments. With an approximate footprint of 30,000 square feet, the new center will facilitate rapid prototyping of new product designs, enhance manufacturing capabilities, and expand research and development capabilities.

WESTWOOD, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Corza Medical (“Corza”) and Envision are pleased to announce today that they have entered into a strategic partnership, combining Corza’s industry-leading innovative surgical technologies, training, and medical education with Envision’s commitment and dedication to programs that center around employment, outreach, rehabilitation, education, and research providing inspiration and opportunity for people who are blind or visually impaired.

WESTWOOD, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Corza Medical (“Corza”) announced strategic plans to directly sell TachoSil®, a best-in-class surgical fibrin sealant patch trusted by medical professionals worldwide, to the U.S. market effective April 2023. Corza Medical acquired TachoSil in January 2021 from Takeda, who previously had Baxter Healthcare distribute TachoSil exclusively in the U.S. market. Corza Medical ended the agreement effective March 31, 2023. The first shipment of U.S. labeled TachoSil was delivered to customers on April 14, 2023.